Portfolia partner Jennifer Fried has always had a passion for bringing ideas to life in healthcare. As a venture capitalist...
A Complicated Journey From VC To ‘Accidental Entrepreneur’ Back To VC
Chicago-based Rising Leader Jennifer Fried spoke to In Vivo about her journey from ‘dream job’ as a VC to ‘accidental entrepreneur’ and co-founder of software company Explorer Surgical, before returning to the VC world. Now working as Portfolia’s venture partner and lead investor, Fried is scouting for innovative companies solving key women’s health issues in areas of clinical unmet needs such as menopause and endometriosis.
More from Leadership
• By
Rapport Therapeutics CEO discusses the company's novel approach to AMPA modulation and why strategic externalization from J&J is accelerating neuroscience innovation.
• By
Merck KGaA's Emre Ozcan outlines the company's systematic approach to integrating digital solutions across the care continuum in specialty pharmaceuticals, moving from technology-first to patient-need-first strategies.
• By
ReproNovo's $65m Series A targets the $1.5bn male infertility market with the first potential oral therapy. Its first-in-class approach to underserved conditions like adenomyosis positions it as an attractive acquisition target in fertility's concentrated market.
• By
Axelyf raises $2.6m seed round for lipid nanoparticle delivery platform on heels of end to US federal support for mRNA vaccines.
More from In Vivo
• By
Rapport Therapeutics CEO discusses the company's novel approach to AMPA modulation and why strategic externalization from J&J is accelerating neuroscience innovation.
• By
Merck KGaA's Emre Ozcan outlines the company's systematic approach to integrating digital solutions across the care continuum in specialty pharmaceuticals, moving from technology-first to patient-need-first strategies.
• By
ReproNovo's $65m Series A targets the $1.5bn male infertility market with the first potential oral therapy. Its first-in-class approach to underserved conditions like adenomyosis positions it as an attractive acquisition target in fertility's concentrated market.